MBL-1

MBL-1 is an orally active anti-inflammatory agent. MBL-1 can be isolated from the fermentation broth of Aspergillus sp. derived from gorgonians. MBL-1 inhibits the activity of the hCOX-2 protein with an IC₅₀ of 5.77 μM. MBL-1 reduces the production of key pro-inflammatory mediators such as NO, ROS, IL-1β and IL-18 by inhibiting the MAPK/NF-κB and NLRP3 signaling pathways. MBL-1 exerts a protective effect against DSS-induced colitis. MBL-1 can be used for the research of ulcerative colitis^[1]. In Vitro:MBL-1 potently inhibits the activity of hCOX-2 protein, with an IC₅₀ value of 5.77 μM^[1].
MBL-1 (0.5-50 μM; 24 h) shows no cytotoxicity in RAW 264.7, J774A.1 and MCF-7 cells even at the highest concentration of 50 μM^[1].
MBL-1 (2-30 μM; 1 h) inhibits NO production in LPS-stimulated RAW 264.7 cells in a dose-dependent manner^[1].
MBL-1 (2-30 μM; 1 h) dose-dependently inhibits LPS-induced ROS production in RAW 264.7 cells ^[1].
MBL-1 (2-30 μM; 1 h) inhibits the production of cytokines IL-6, IL-10 and IL-1β in LPS-stimulated RAW 264.7 cells in a dose-dependent manner^[1].
MBL-1 (2-30 μM) dose-dependently inhibits LPS-induced phosphorylation of p38, ERK and JNK proteins in RAW 264.7 cells^[1]. In Vivo:MBL-1 (25-50 mg/kg; p.o.; once daily) exerts significant dose-dependent protective effects against DSS-induced acute colitis in male C57BL/6 J mice^[1].